Coronavirus information from UCLA and UCLA Health.

Nammi Therapeutics, Inc. is a pre-clinical stage biotech company focused on optimizing cancer immunotherapy by using nanocarriers to deliver synergistic anti-tumor and immune activating agents to the tumor.

Market:

Nammi Therapeutics products offer broad potential for efficacy across many solid tumor indications, thus providing a robust market opportunity in the multi-billion dollar range, while they are expected to reduce the cost of treating cancer through lower cost of goods and reduced cost of managing treatment related toxicities.

Technology:

Nammi's technology utilizes nanocarriers to deliver synergistic anti-tumor and immunomodulatory combinations to the tumor microenvironment. An immunogenic cell death inducing chemotherapy primes the cancer site for recruitment of cytotoxic T cells in solid tumors. The response is sustained and synergistically enhanced by co-delivery of an immune adjuvant. The combined effect represents a unique mechanism of action providing a robust, systemic anti-tumor immune response, which can eliminate primary and metastatic disease, with immune memory.

Advantages:

  • Reduces off-target toxicity and provides greater efficacy
  • Provides optimal immunotherapy combinations in a single therapy
  • Lower cost to patients and reduced hospital costs due to lower toxicity
  • Current therapies only work in a minority of solid tumor patients

Development Stage:

  • Pre-clinical

Patents Issued:

  • PCT/US20 18/033265: NANO-ENABLED IMMUNOTHERAPY IN CANCER (18 May 2017)

Select Publications:

Contact:

Email: info@NAmmiRX.com
Phone: 424-901-6696
Website: www.NAmmiRX.Com
Portfolio Companies